An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex® (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors
Phase 2
N/A
N/A
N/A
N/A
Not Enrolling
Female
Breast Neoplasms
Female
Breast Neoplasms
Trial Information
An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex® (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors
Inclusion Criteria:
- Histological/cytological confirmation of breast cancer
- progression under treatment with an aromatase inhibitor
- At least one measurable or non-measurable lesion
Exclusion Criteria:
- Prior treatment for breast cancer with more than 2 different hormonal agents
- More than 1 chemotherapy for advanced disease
- Presence of life-threatening metastatic visceral disease
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Clinical Benefit Rate
Principal Investigator
AstraZeneca Switzerland Medical Director, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
Switzerland: Swissmedic
Study ID:
9238SZ/0001
NCT ID:
NCT00272740
Start Date:
March 2000
Completion Date:
Related Keywords:
- Breast Neoplasms
- breast cancer
- fulvestrant
- Faslodex
- hormonotherapy
- aromatase inhibitor failure
- Advanced breast cancer
- Breast Neoplasms
- Neoplasms
Name | Location |
|---|
